Stryker Corporation

New York Stock Exchange
Back to all articles
Bullish +60

Surgical Robotics Meets AI: Intuitive Surgical, Medtronic, and Stryker Are the Sleeper Plays of the Healthcare Boom

AI-generated analysis

🤖 Intuitive Surgical reported Q1 FY26 non-GAAP EPS of $2.50, beating the $2.11 estimate by 18.66% and driving revenue growth of 22.96% year over year.

📈 Intuitive's installed base grew with 11,395 da Vinci systems (up 12%) and 1,041 Ion systems (up 22%), feeding procedural data to digital platforms.

💰 Intuitive Surgical holds $7.98 billion in cash after repurchasing 2.3 million shares for $1.1 billion during the quarter.

🔍 Medtronic received FDA clearance for its Hugo robotic-assisted surgery system with first cases completed in February 2026.

❤️ Medtronic's Cardiac Ablation Solutions saw revenue jump 80% overall and 137% in the United States driven by pulsed field ablation.

📊 Medtronic delivered Q3 FY26 non-GAAP EPS of $1.36, topping the $1.3351 consensus with organic revenue growth of 6%.

⚠️ Stryker reported Q1 FY26 adjusted EPS of $2.60, missing the $2.98 estimate due to a March 11, 2026 cybersecurity incident.

💸 Stryker recorded $118 million in structural optimization charges that compressed its adjusted operating margin to 21.1% from 22.9%.

📉 Stryker shares are down 21.3% over the past year, while Intuitive Surgical shares are down 24.3% year to date.

🎯 All three companies maintain full-year guidance despite recent headwinds, with Intuitive expecting 13.5% to 15.5% da Vinci procedure growth.

Bullish Signals
  • Intuitive Surgical achieved its fourth consecutive EPS beat and revenue grew 22.96% year over year, anchored by high-margin Instruments & Accessories.
  • Medtronic's Cardiac Ablation Solutions drove an 80% overall revenue increase and 137% growth in the United States via pulsed field ablation technology.
  • Intuitive Surgical expanded its installed base with a 22% increase in Ion systems and a 12% increase in da Vinci systems, strengthening its data flywheel.
  • Medtronic delivered organic revenue growth of 6% ahead of guidance following FDA clearance for the Hugo robotic system and Stealth AXiS Surgical System.
  • Intuitive Surgical maintains a strong balance sheet with $7.98 billion in cash and active share repurchases, supporting shareholder returns.
Risk Factors
  • Stryker missed Q1 FY26 EPS and revenue estimates due to a cybersecurity incident and $118 million in structural optimization charges.
  • Stryker's adjusted operating margin compressed from 22.9% to 21.1%, and Mako revenue is bundled, preventing investors from isolating the AI orthopedics flywheel.
  • Intuitive Surgical faces a 1.0% margin headwind from tariff exposure across Mexico, Germany, and China.
  • Medtronic experienced a slip in non-GAAP gross margin to 64.9% from 66.6%, with a $185 million tariff headwind baked into FY26 guidance.
  • Intuitive Surgical's shares are down 24.3% year to date, testing institutional patience despite strong operational performance.
Full Analysis
The article analyzes three major medical device companies—Intuitive Surgical (ISRG), Medtronic (MDT), and Stryker (SYK)—as key beneficiaries of the convergence between surgical robotics and artificial intelligence. It argues that these firms possess durable competitive moats through large installed bases of robotic systems that generate structured data for training, guidance, and predictive analytics, creating a flywheel effect distinct from pure software stocks. Intuitive Surgical is highlighted as the purest expression of this thesis, reporting its fourth consecutive EPS beat in Q1 FY26 with revenue growth driven by high-margin instruments. The company's installed base of da Vinci and Ion systems expanded significantly, feeding data to digital platforms, while maintaining strong cash reserves despite tariff headwinds. Medtronic is noted for recent regulatory milestones, including FDA clearance for its Hugo robotic system and significant revenue growth in Cardiac Ablation Solutions driven by pulsed field ablation technology. The company delivered a non-GAAP EPS beat in Q3 FY26, though margins slipped slightly due to tariffs. Stryker reported mixed results with adjusted EPS missing estimates due to a cybersecurity incident and structural optimization charges. Despite the cyber event and bundled Mako revenue making isolation difficult, the company maintained full-year guidance for organic sales growth, positioning its Ortho Tech stack as a key area for future AI integration.